Rabbit anti-Mouse CD252 (OX40 Ligand) Monoclonal Antibody for IF/ICC, FC - P43488

Core Product Specifications and Parameters

Biological Background: CD252 (OX40 Ligand) Function and Localization

• Tumor necrosis factor ligand superfamily member 4 (TNFSF4), commonly known as OX40 ligand (OX40L), is encoded by the Tnfsf4 gene in mice (UniProt P43488).
• It is a type II transmembrane protein anchored to the cell membrane, containing an extracellular C‑terminal TNF homology domain.
• Functions as a cytokine by binding to its receptor TNFRSF4 (OX40), thereby co‑stimulating T‑cell proliferation and cytokine production.
• Characterized as a glycoprotein with disulfide bond formation essential for its structural stability.
• The three‑dimensional structure of OX40L has been determined (PDB), revealing a homotrimeric assembly typical of TNF family ligands.
• Post‑translational modifications include N‑linked glycosylation; the protein migrates at approximately 22 kDa on SDS‑PAGE.

Experimental Guidance and Technical Tips

• As a directly conjugated antibody, it streamlines IF/ICC and flow cytometry workflows by eliminating the need for a secondary antibody.
• For IF/ICC, consider fixing cells with 4% paraformaldehyde; because CD252 is a surface membrane protein, permeabilization with 0.1% Triton X‑100 may be omitted unless intracellular epitopes are targeted.
• The immunogen (aa 51‑198) lies within the extracellular domain, ensuring recognition of native surface‑exposed OX40L in live‑cell flow cytometry
• Empirical dilution optimization is recommended using a relevant mouse cell line known to express OX40L.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is a comprehensive partner for IVD raw‑material procurement, serving diagnostic manufacturers, laboratories, and research institutes. This anti‑mouse CD252 (OX40L) antibody targets a pivotal immune co‑stimulatory molecule, supporting immunology and inflammation studies. In addition to validated antibodies, CamelBio supplies ready‑to‑use antibody pairs, bulk ancillary reagents, and custom sourcing for rare‑target raw materials—helping you accelerate development from concept to clinic.